{"id":72199,"date":"2026-08-11T11:54:49","date_gmt":"2026-08-11T03:54:49","guid":{"rendered":"https:\/\/flcube.com\/?p=72199"},"modified":"2026-08-11T11:54:50","modified_gmt":"2026-08-11T03:54:50","slug":"xinno-biotechnology-and-statia-biopharma-sign-exclusive-deal-to-develop-sta528-transdermal-therapy-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72199","title":{"rendered":"Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Xinno Biotechnology (Jiashan) Co., Ltd.<\/strong> announced an <strong>exclusive technology collaboration agreement<\/strong> with US\u2011based <strong>Statia Biopharma, Inc.<\/strong> to jointly develop an <strong>innovative transdermal formulation<\/strong> of <strong>STA528<\/strong>, a novel drug candidate for <strong>autoimmune diseases<\/strong>. The partnership covers both <strong>formulation product development (PD)<\/strong> and <strong>global business development (BD)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-overview\" class=\"wp-block-heading\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Xinno Biotechnology (Jiashan) Co., Ltd. \u00d7 Statia Biopharma, Inc.<\/td><\/tr><tr><td><strong>Deal Type<\/strong><\/td><td>Exclusive technology collaboration<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>STA528 \u2013 transdermal formulation<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Formulation product development (PD) + global business development (BD)<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>Xinno Bio&#8217;s proprietary HETDS (High\u2011Efficiency Transdermal Delivery System)<\/td><\/tr><tr><td><strong>Target Indications<\/strong><\/td><td>Rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA), systemic lupus erythematosus (SLE)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>10 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> STA528, lead candidate of Statia Biopharma, a US biotech focused on innovative therapies for autoimmune diseases<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>Phospho\u2011Specific STAT3<\/strong> \u2013 a novel mechanism of action<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Inhibits the inflammatory signaling pathway mediated by STAT3 phosphorylation, thereby modulating aberrant immune responses<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Offers a differentiated, first\u2011in\u2011class\u2011style approach distinct from traditional JAK inhibitor therapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-2-us-ulcerative-colitis\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase 2 (US, Ulcerative Colitis)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Status<\/strong><\/td><td>Phase 2 completed in the US<\/td><\/tr><tr><td><strong>Efficacy<\/strong><\/td><td>Favorable clinical efficacy demonstrated<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Favorable safety profile observed<\/td><\/tr><tr><td><strong>Key Advantage<\/strong><\/td><td>Avoided adverse effects commonly associated with traditional <strong>JAK inhibitors<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The Phase 2 readout provides a clinical foundation for expanding STA528 into additional autoimmune indications via a transdermal route.<\/p>\n\n\n\n<h2 id=\"h-technology-platform-hetds\" class=\"wp-block-heading\">Technology Platform \u2013 HETDS<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Proprietary System:<\/strong> Xinno Bio&#8217;s <strong>High\u2011Efficiency Transdermal Delivery System (HETDS)<\/strong><\/li>\n\n\n\n<li><strong>Objective:<\/strong> Optimize STA528&#8217;s <strong>pharmacokinetic properties<\/strong> and <strong>safety profile<\/strong> through transdermal delivery<\/li>\n\n\n\n<li><strong>Potential Benefits:<\/strong> Improved exposure control, reduced systemic side effects, and enhanced patient compliance versus oral dosing<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication Breadth:<\/strong> RA, psoriasis, PsA and SLE collectively represent multi\u2011billion\u2011dollar global autoimmune markets with significant unmet need for safer chronic therapies.<\/li>\n\n\n\n<li><strong>Safety Positioning:<\/strong> A STAT3\u2011pathway inhibitor that avoids JAK\u2011inhibitor\u2011class adverse effects could be attractive to physicians and payers seeking differentiated risk profiles.<\/li>\n\n\n\n<li><strong>Strategic Fit:<\/strong> The deal pairs Statia&#8217;s novel mechanism asset with Xinno&#8217;s transdermal delivery expertise \u2014 a structure designed to support both formulation innovation and global out\u2011licensing optionality.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the collaboration&#8217;s development plans, formulation outcomes, and commercial potential for STA528. Actual results may differ due to risks including clinical outcomes, regulatory pathways, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Xinno Biotechnology (Jiashan) Co., Ltd. announced an exclusive technology collaboration agreement with US\u2011based Statia Biopharma,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4882,4881],"class_list":["post-72199","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-statia-biopharma","tag-xinno-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Xinno Biotechnology (Jiashan) Co., Ltd. announced an exclusive technology collaboration agreement with US\u2011based Statia Biopharma, Inc. to jointly develop an innovative transdermal formulation of STA528, a novel drug candidate for autoimmune diseases. The partnership covers both formulation product development (PD) and global business development (BD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72199\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"Xinno Biotechnology (Jiashan) Co., Ltd. announced an exclusive technology collaboration agreement with US\u2011based Statia Biopharma, Inc. to jointly develop an innovative transdermal formulation of STA528, a novel drug candidate for autoimmune diseases. The partnership covers both formulation product development (PD) and global business development (BD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72199\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-11T03:54:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-11T03:54:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72199#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72199\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases\",\"datePublished\":\"2026-08-11T03:54:49+00:00\",\"dateModified\":\"2026-08-11T03:54:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72199\"},\"wordCount\":399,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Statia Biopharma\",\"Xinno Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72199#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72199\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72199\",\"name\":\"Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-11T03:54:49+00:00\",\"dateModified\":\"2026-08-11T03:54:50+00:00\",\"description\":\"Xinno Biotechnology (Jiashan) Co., Ltd. announced an exclusive technology collaboration agreement with US\u2011based Statia Biopharma, Inc. to jointly develop an innovative transdermal formulation of STA528, a novel drug candidate for autoimmune diseases. The partnership covers both formulation product development (PD) and global business development (BD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72199#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72199\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72199#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Xinno Biotechnology (Jiashan) Co., Ltd. announced an exclusive technology collaboration agreement with US\u2011based Statia Biopharma, Inc. to jointly develop an innovative transdermal formulation of STA528, a novel drug candidate for autoimmune diseases. The partnership covers both formulation product development (PD) and global business development (BD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72199","og_locale":"en_US","og_type":"article","og_title":"Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases","og_description":"Xinno Biotechnology (Jiashan) Co., Ltd. announced an exclusive technology collaboration agreement with US\u2011based Statia Biopharma, Inc. to jointly develop an innovative transdermal formulation of STA528, a novel drug candidate for autoimmune diseases. The partnership covers both formulation product development (PD) and global business development (BD).","og_url":"https:\/\/flcube.com\/?p=72199","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-11T03:54:49+00:00","article_modified_time":"2026-08-11T03:54:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72199#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72199"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases","datePublished":"2026-08-11T03:54:49+00:00","dateModified":"2026-08-11T03:54:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72199"},"wordCount":399,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Statia Biopharma","Xinno Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72199#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72199","url":"https:\/\/flcube.com\/?p=72199","name":"Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-11T03:54:49+00:00","dateModified":"2026-08-11T03:54:50+00:00","description":"Xinno Biotechnology (Jiashan) Co., Ltd. announced an exclusive technology collaboration agreement with US\u2011based Statia Biopharma, Inc. to jointly develop an innovative transdermal formulation of STA528, a novel drug candidate for autoimmune diseases. The partnership covers both formulation product development (PD) and global business development (BD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72199#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72199"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72199#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72199"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72199\/revisions"}],"predecessor-version":[{"id":72245,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72199\/revisions\/72245"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}